Dopamine-derived biological reactive intermediates and protein modifications: Implications for Parkinson's disease.
Dopamine (DA) undergoes monoamine oxidase catalyzed oxidative deamination to 3,4-dihydroxyphenylacetaldehyde (DOPAL), which is metabolized primarily to 3,4-dihydroxyphenylacetic acid (DOPAC) via aldehyde dehydrogenase (ALDH). Previous studies demonstrated DOPAL to be neurotoxic, more so than DA and other metabolites, and implicated the aldehyde intermediate as a factor in the pathogenesis of Parkinson's disease (PD). However, the mechanism for generation of DOPAL at aberrant levels and the pathways for toxicity are not conclusively known. Various models for DA catabolism revealed the susceptibility of DOPAL biotransformation (e.g., ALDH) to products of oxidative stress, e.g., 4-hydroxy-2-nonenal, at physiologic/pathologic levels and agents that induce oxidative stress. An elevated concentration of DOPAL correlated with increased protein modification with subsequent work demonstrating significant reactivity of the DA-derived electrophile toward protein nucleophiles compared to DA and other metabolites, e.g., DOPAC. The addition of DOPAL to proteins proceeds via reaction of the aldehyde with Lys residues, yielding a Schiff base; however, post-adduction chemistry occurs for the DOPAL-modification resulting in protein cross-linking. Preliminary work indicates enzymes in DA synthesis and catabolism to be cellular targets for DOPAL. Functional consequences for elevated levels of the DA-derived aldehyde and protein modification may include adverse cellular effects. These data implicate DOPAL as a toxic and reactive intermediate potentially serving as a "chemical trigger" for some stage of PD pathogenesis.
Division of Medicinal and Natural Products Chemistry, College of Pharmacy, The University of Iowa, Iowa City, IA 52242-1112, USA.
Yunden
Y
Jinsmaa
Virginia R
VR
Florang
Jennifer N
JN
Rees
Lydia M
LM
Mexas
Laurie L
LL
Eckert
Erin M G
EM
Allen
David G
DG
Anderson
Jonathan A
JA
Doorn
D000818:Animals; D002460:Cell Line; D004298:Dopamine / Q000737:chemistry*; D010300:Parkinson Disease / Q000378:metabolism*; D011506:Proteins / Q000737:chemistry*
D011506:Proteins; D004298:Dopamine
Pharmacol Rev. 2007 Jun;59(2):125-50
17379813
Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2696-701
8610103
J Neurosci Res. 2000 May 15;60(4):552-8
10797558
J Neurochem. 1989 Feb;52(2):381-9
2911023
J Neurochem. 1987 May;48(5):1566-72
3559567
Neurotoxicology. 2005 Aug;26(4):701-19
16112328
Eur J Neurol. 2011 May;18(5):703-10
21073636
Brain Res. 2003 Nov 7;989(2):205-13
14556942
Biochem Pharmacol. 1973 Aug 1;22(15):1905-13
4722459
PLoS One. 2010 Dec 13;5(12):e15251
21179455
J Neurochem. 1995 Apr;64(4):1645-54
7891092
Neurotoxicology. 2007 Jan;28(1):76-82
16956664
Chem Res Toxicol. 2007 Oct;20(10):1536-42
17887726
Mol Pharmacol. 1978 Jul;14(4):633-43
98706
Pharmacol Rev. 2004 Sep;56(3):331-49
15317907
Hepatology. 1991 Apr;13(4):728-34
2010168
Nat Med. 2005 Nov;11(11):1214-21
16227987
Curr Drug Targets CNS Neurol Disord. 2003 Apr;2(2):143-8
12769806
J Biol Chem. 1997 Feb 28;272(9):5727-31
9038184
Chem Res Toxicol. 2009 May;22(5):835-41
19388687
Ann Neurol. 2003;53 Suppl 3:S26-36; discussion S36-8
12666096
Neurotoxicology. 1991 Fall;12(3):473-92
1720882
Toxicol Lett. 1982 Nov;14(1-2):35-43
7157414
J Neurochem. 1998 Oct;71(4):1607-15
9751194
J Neurochem. 1994 Sep;63(3):1126-32
8051554
Neurotoxicology. 2004 Jan;25(1-2):101-15
14697885
Environ Health Perspect. 2005 Sep;113(9):1230-3
16140633
Biochem J. 1997 May 15;324 ( Pt 1):25-8
9164836
Free Radic Biol Med. 2008 Jun 1;44(11):1873-86
18342017
Free Radic Biol Med. 1991;11(1):81-128
1937131
Chem Res Toxicol. 2009 Jul;22(7):1256-63
19537779
Free Radic Biol Med. 2001 Dec 1;31(11):1473-85
11728820